Menu Search
Equities

Qiagen NV

QGEN:NYQ

Qiagen NV

Actions
Health CareMedical Equipment and Services
  • Price (USD)43.23
  • Today's Change-0.82 / -1.86%
  • Shares traded933.45k
  • 1 Year change+10.21%
  • Beta0.3535
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform5
Hold10
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Qiagen NV have a median target of 50.00, with a high estimate of 60.00 and a low estimate of 42.50. The median estimate represents a 13.51% increase from the last price of 44.05.
High36.2%60.00
Med13.5%50.00
Low-3.5%42.50

Earnings history & estimates in USD

On Nov 06, 2024, Qiagen NV reported 3rd quarter 2024 earnings of 0.57 per share. This result was in line with the consensus of the 12 analysts following the company and exceeded last year's 3rd quarter results by 10.68%.
The next earnings announcement is expected on Feb 10, 2025.
Average growth rate+3.41%
Qiagen NV reported annual 2023 earnings of 2.07 per share on Feb 06, 2024.
Average growth rate+11.95%
More ▼

Revenue history & estimates in USD

Qiagen NV had 3rd quarter 2024 revenues of 502.00m. This bettered the 491.75m consensus of the 11 analysts covering the company. This was 3.42% above the prior year's 3rd quarter results.
Average growth rate+1.61%
Qiagen NV had revenues for the full year 2023 of 1.97bn. This was 8.23% below the prior year's results.
Average growth rate+7.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.